Home > Journals > The Quarterly Journal of Nuclear Medicine and Molecular Imaging > Past Issues > The Quarterly Journal of Nuclear Medicine and Molecular Imaging 2013 June;57(2) > The Quarterly Journal of Nuclear Medicine and Molecular Imaging 2013 June;57(2):146-52

CURRENT ISSUE
 

ARTICLE TOOLS

Reprints

THE QUARTERLY JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING

A Journal on Nuclear Medicine and Molecular Imaging


A Journal on Nuclear Medicine and Molecular Imaging
Affiliated to the Society of Radiopharmaceutical Sciences and to the International Research Group of Immunoscintigraphy
Indexed/Abstracted in: Current Contents/Clinical Medicine, EMBASE, PubMed/MEDLINE, Science Citation Index (SciSearch), Scopus
Impact Factor 2,481


eTOC

 

REVIEWS  MIBG IN THE DIAGNOSIS AND THERAPY OF PHEOCHROMOCYTHOMA AND PARAGANGLIOMA


The Quarterly Journal of Nuclear Medicine and Molecular Imaging 2013 June;57(2):146-52

Copyright © 2013 EDIZIONI MINERVA MEDICA

language: English

Iodine-131 metaiodobenzylguanidine (I-131 MIBG) diagnosis and therapy of pheochromocytoma and paraganglioma: current problems, critical issues and presentation of a sample case

Castellani M. R. 1, Aktolun C. 2, Buzzoni R. 3, Seregni E. 1, Chiesa C. 1, Maccauro M. 1, Aliberti G. L. 1, Vellani C. 1, Lorenzoni A. 1, Bombardieri E. 1

1 Nuclear Medicine Division, Istituto Nazionale Tumori IRCCS Foundation, Milan, Italy; 2 Molecular Imaging Program at Stanford (MIPS) Department of Radiology, Stanford University School of Medicine, Stanford, CA, USA; 3 Medical Oncology, Day Hospital Unit, IRCCS Istituto Nazionale dei Tumori Foundation, Milan, Italy


PDF  


Iodine-131 metaiodobenzylguanidine (I-131 MIBG) has been used for the diagnosis and treatment of malignant pheochromocytomas (PHEO) and paragangliomas (PGL) since 1980’s. Despite increasing amount of experience with iodine-131 (I-131) MIBG therapy, many important questions still exist. In this article, we will discuss the current problems learned from clinical experience in diagnosis and therapy of PHEO/PGL with I-131 MIBG, and present a sample case to emphasize the critical aspects for an optimal treatment strategy.

top of page

Publication History

Cite this article as

Corresponding author e-mail

rita.castellani@istitutotumori.mi.it